Brain Disease Modalities and Software Market – A Global and Regional Analysis: Focus on Product, Indication, Patient Type, End User, and Regional Analysis – Analysis and Forecast, 2022-2031

$5,250$8,100

The brain disease modalities and software market was valued at $13,055.7 million in 2021 and is expected to reach $21,867.6 million by the end of 2031. The market is expected to grow at a CAGR of 5.31% during the forecast period from 2022 to 2031.

Description

Market Report Coverage – Brain Disease Modalities and Software Market

Market Segmentation

• Indication – Brain Diseases (Brain and Central Nervous System Cancer, Idiopathic Epilepsy, Ischemic stroke, and Other Brain Diseases) and Neurodegenerative Diseases (Alzheimer’s Disease, Multiple Sclerosis, Parkinson’s Disease, Motor Neuron Disease, and Other Neurodegenerative Diseases)
• Patient Type – Adults and Paediatrics and Infants
• End User – Hospitals and Clinics, Ambulatory Surgery Centers, and Diagnostic Imaging Centers
• Product Type – Brain Imaging Modalities (PET Devices, CT Devices, MRI Devices, PET-CT, and PET-MRI) and Brain Analysis Software

Regional Segmentation

• North America – U.S. and Canada
• Europe – Germany, U.K., Spain, Italy, France, and Rest-of-Europe
• Asia-Pacific – Japan, China, South Korea, India, Australia and New Zealand, and Rest-of-Asia-Pacific
• Rest-of-the-World – Latin America and Middle East and Africa

Market Growth Drivers

• Increasing Prevalence of Neurological Disorders
• Rising AI Integration in the Field of Medical Imaging
• Increasing Demand for Safer and Non-Invasive Devices for Medical Imaging

Market Challenges

• High Upfront Cost of Imaging Devices
• Declining Availability of Helium

Market Opportunities

• Integration of Imaging Solutions with Novel Biomarkers to Enable Diagnosis of a Wider Range of Neurological Disorders
• Integration of 3D Amplified MRI, a New Technological Advancement

Key Companies Profiled

United Imaging Healthcare Co., Ltd., Koninklijke Philips N.V., General Electric Company, Canon, Inc., Siemens Healthineers AG, Vuno Co., Ltd., Fujifilm Holdings Corporation, Aspect Imaging, IXICO, QMENTA, Cortechs.ai, Quantib, Brainomix, Qure.AI, Imaging Biometrics, LLC, A.I. Analysis, Inc.

How This Report Can Add Value

Assuming that the reader is a developer of brain disease modalities and software, they will be able to do the following:

• Understand their position as compared to some of the key players in the market
• Stay updated with novel technology integration, features, and the latest developments in the market
• Understand the impact of COVID-19 on the adoption of brain disease modalities and software and the entry barriers as a result of it
• Gain insights into which regions to target globally based on factors such as the amount of technology integration in medical imaging and the quality of access to affordable medical imaging
• Gain insights into the end user perception with respect to the adoption of imaging modalities and software
• Identify some of the key players in the market and understand their valuable contribution

Key Questions Answered in the Global Brain Disease Modalities and Software Market Report

• How has COVID-19 impacted the adoption of brain imaging modalities and software?
• What are the key regulations governing the brain disease modalities and software market in key regions?
• Which technological developments are projected to have the maximum influence on the global brain disease modalities and software market?
• Who are the leading players holding significant dominance in the global brain disease modalities and software market currently?
• What are the drivers and restraints for the global brain disease modalities and software market?
• Which region has the highest growth rate in the global brain disease modalities and software market?
• Who are the emerging companies in the global brain disease modalities and software market?

Brain Disease Modalities and Software Market Industry Overview

Brain imaging modalities include conventional modalities such as MRI and CT scans and the more emerging imaging technologies such as PET and combined functionalities of PET with MRI or CT. While MRI is a conventional technology due to its age-long usage, various advanced MRI techniques such as diffusion tensor imaging (DTI), diffusion-weighted imaging (DWI), susceptibility-weighted imaging (SWI), and dynamic susceptibility contrast (DSC) imaging are being employed more widely in regions such as North America and Europe.

Brain imaging software offers a valuable addition to the scanned images obtained through these modalities with respect to quantitative analysis. Quantitative insights into the structure, biomarkers, and other subtle abnormalities in the brain are a valuable tool in aiding in a more accurate diagnosis of neurological disorders.

The global brain disease modalities and software market report highlights that the market was valued at $13,055.7 million in 2021 and is expected to reach $21,867.6 million by the end of 2031. The market is expected to grow at a CAGR of 5.31% during the forecast period from 2022 to 2031.

Global Brain Disease Modalities and Software Market Drivers

The market is driven by factors such as the increasing prevalence of neurological disorders, the rising AI integration in the field of medical imaging, and the increasing demand for safer and non-invasive devices for medical imaging.

There has been a paradigm shift in patient preference from invasive to minimally invasive modes of diagnosis as well as treatment. MRI, CT, and PET-CT scans are popular non-invasive methods of medical imaging that produce three-dimensional images of the body to aid in the diagnosis of diseases. Furthermore, there is also a rising preference for safer imaging technologies that employ minimal radiation.

Global Brain Disease Modalities and Software Market Challenges

The factors restraining market growth include the high upfront cost of imaging devices and the declining availability of helium. Hardware devices for medical imaging, such as MRI, CT, and PET-CT scanners, are capital-intensive equipment with a high upfront cost. Lack of affordability is a major factor restraining the growth of the market in emerging economies such as Latin America and Middle East and Africa. Due to the expensive nature of these imaging modalities, there is a considerable lack of accessibility across the population. As a result, the low- and middle-income population usually relies on alternative clinical tests such as blood biomarker tests and cognitive scoring tests as a preliminary method to diagnose neurological disorders.

Furthermore, the shortage of helium globally particularly affects the field of medical imaging in the healthcare sector. MRI scanners require a sufficient quantity of liquid helium, below which the functioning of the scanner is compromised. Therefore, challenges faced by manufacturers of medical imaging modalities associated with the procurement of supercooled liquid helium have a direct effect on the smooth functioning of the machine, thereby hindering the growth of the market.

Global Brain Disease Modalities and Software Market Opportunities

The opportunity for growth of the global brain disease modalities and software market lies in the integration of imaging solutions with novel biomarkers to enable diagnosis of a wider range of neurological disorders and integration of 3D amplified MRI, a new technological advancement in the field of brain imaging.

This new development, i.e., 3D amplified MRI, enables physicians to view pulsations of the brain as opposed to a conventional static MRI image. The real-time visualization of brain movement holds significant potential to detect hard-to-find abnormalities, thereby aiding in the diagnosis process. Companies in the global brain disease modalities and software market can leverage this new technological advancement to gain a competitive edge in the market.

Impact of COVID-19 on the Global Brain Disease Modalities and Software Market

There was a decline in the demand for neuroimaging services as it was offset by the demand for respiratory imaging and tests for COVID-19 treatment. The need to fulfill the demand for critical supplies for COVID-19 management, such as pulse oximeters, ventilators, and oxygen concentrators, overshadowed the demand and supply of the neuroimaging modalities. Although the neuroimaging market is experiencing overall growth, most of the hospitals have reallocated their budget to stock the resources required to fight COVID-19 as they appear to be more crucial.

The COVID-19 pandemic led to government-mandated travel restrictions, especially during the peak phases, leading to a shifting preference among the global population from physical visits to home-based care. This has led to a further push in demand for wearable imaging scanners that can be used at home. They could potentially decrease the demand for hospital-based imaging devices and software due to the ease of providing diagnoses to the patients.

Market Segmentation

Global Brain Disease Modalities and Software Market (by Product)

The global brain disease modalities and software market has been segmented on the basis of product type into brain modalities (PET devices, PET-CT, PET-MRI, CT devices, and MRI devices) and brain analysis software.

Global Brain Disease Modalities and Software Market (by Indication)

The global brain disease modalities and software market has been segmented on the basis of indication into two major segments, namely, brain diseases (brain and central nervous system cancer, idiopathic epilepsy, ischemic stroke, and other brain diseases) and neurodegenerative diseases (Alzheimer’s disease, multiple sclerosis, Parkinson’s disease, motor neuron disease, and other neurodegenerative diseases). Brain diseases could have several underlying causes spanning illness, injury, or genetic manifestations. To diagnose any brain disorder, the initial steps undertaken include preliminary blood tests and understanding the family’s medical background. In addition, an imaging scan is a popular method to detect any abnormalities in brain structure, and tests such as electroencephalogram (EEG) can also be conducted to analyze the underlying electrical activity in the brain.

Global Brain Disease Modalities and Software Market (by Region)

The different regions covered under the global brain disease modalities and software market include North America, Europe, Asia-Pacific, and Rest-of-the-World.

North America and Europe are two of the largest markets for brain disease modalities and software, while developing countries are expected to register strong growth in their adoption in the near future.

Key Market Players and Competition Synopsis

Some of the key players operating in the market include United Imaging Healthcare, Koninklijke Philips N.V., General Electric Company, Canon Inc., Siemens Healthineers AG, Vuno Co., Ltd., Fujifilm Holdings Corporation, Aspect Imaging, IXICO, QMENTA, Cortechs.ai, Quantib, Brainomix, Qure.AI, Imaging Biometrics and A.I., and Analysis, Inc.

In the past few years, the global brain disease modalities and software market has witnessed several strategic and technological developments undertaken by the different market players to attain their respective market shares in this emerging domain. Some of the strategies covered in this segment are funding activities, mergers and acquisitions (M&A), partnerships, alliances, and business expansions, regulatory and legal activities, and new offerings. The preferred strategy for companies has been regulatory and legal activities followed by partnerships and business expansions.

Related: Global Brain Imaging Modalities Market – A Global and Regional Analysis: Focus on Product Type, Patient Age, End User, and Regional Analysis – Analysis and Forecast, 2022-2031

Additional information

Publisher

Geography Covered

Date Published

Pages

Format

Base Year

2022

Base Market Size

$13, 731.2 Million in 2022

Currency

USD

Forecast Year

2031

Market Size Forecast

$21, 867.6 Million by 2031

CAGR

5.31%

Table of Contents

1 Markets
1.1 Market Outlook
1.1.1 Product Definition
1.1.2 Inclusion and Exclusion Criteria
1.1.3 Key Findings
1.1.4 Market Growth Scenario
1.1.4.1 Realistic Growth
1.1.4.2 Optimistic Growth
1.1.4.3 Pessimistic/Conservative Growth
1.2 Industry Outlook
1.2.1 Technology Landscape
1.2.1.1 Key Trends
1.2.1.1.1 Integration of Hardware and Software Solutions for Imaging
1.2.1.1.2 Investigation of Ensemble Models that Involve Multiple Classifiers such as Biomarkers and Patient Features
1.2.1.1.3 Rising Preference for Portable Brain Scanners and Wearables
1.2.1.1.4 Integration of Augmented Reality with Medical Imaging
1.2.1.1.5 Increased Focus on Targeting the Pediatric Population
1.2.2 Opportunity Assessment
1.2.2.1 Short-Term Potential
1.2.2.2 Long-Term Potential
1.2.3 Product Benchmarking
1.2.4 Patent Analysis
1.2.4.1 Patent Analysis by Country/Cluster
1.2.4.2 Patent Analysis by Year
1.3 Impact of COVID-19 on the Global Brain Disease Modalities and Software Market
1.3.1 Impact on Facilities
1.3.2 Impact on Modalities Adoption
1.3.3 Impact on Market Size
1.3.3.1 Pre-COVID-19 Phase
1.3.3.2 During-COVID-19 Phase
1.3.3.3 Post-COVID-19 Phase
1.4 Business Dynamics
1.4.1 Impact Analysis
1.4.2 Business Drivers
1.4.2.1 Increasing Prevalence of Neurological Disorders
1.4.2.2 Rising AI Integration in the Field of Medical Imaging
1.4.2.3 Increasing Demand for Safer and Non-Invasive Devices for Medical Imaging
1.4.3 Business Restraints
1.4.3.1 High Upfront Cost of Imaging Devices
1.4.3.2 Declining Availability of Helium
1.4.4 Business Opportunities
1.4.4.1 Integration of Imaging Solutions with Novel Biomarkers to Enable Diagnosis of a Wider Range of Neurological Disorders
1.4.4.2 Integration of 3D Amplified MRI, a New Technological Advancement
2 Application
2.1 Brain Disease Modalities and Software Market (by Indication)
2.1.1 Opportunity Assessment
2.1.2 Growth Share Matrix
2.1.3 Brain Diseases
2.1.3.1 Patient Volume
2.1.3.2 Brain and Central Nervous System Cancer
2.1.3.2.1 Market Trend
2.1.3.2.2 Market Size and Forecast
2.1.3.2.3 Examination Process
2.1.3.2.4 Key Modalities Analysis
2.1.3.3 Idiopathic Epilepsy
2.1.3.3.1 Market Trend
2.1.3.3.2 Market Size and Forecast
2.1.3.3.3 Examination Process
2.1.3.3.4 Key Modalities Analysis
2.1.3.4 Ischemic Stroke
2.1.3.4.1 Market Trend
2.1.3.4.2 Market Size and Forecast
2.1.3.4.3 Examination Process
2.1.3.4.4 Key Modalities Analysis
2.1.3.5 Other Brain Diseases
2.1.3.5.1 Market Trend
2.1.3.5.2 Market Size and Forecast
2.1.3.5.3 Examination Process
2.1.3.5.4 Key Modalities Analysis
2.1.4 Neurodegenerative Diseases
2.1.4.1 Patient Volume
2.1.4.2 Key Examination Process for Disease Confirmation
2.1.4.3 Alzheimer’s Disease
2.1.4.3.1 Market Trend
2.1.4.3.2 Market Size and Forecast
2.1.4.3.3 Medical Bill and Fee
2.1.4.3.3.1 North America
2.1.4.3.3.2 Europe
2.1.4.3.3.3 Asia-Pacific
2.1.4.3.3.4 Rest-of-the-World
2.1.4.4 Multiple Sclerosis
2.1.4.4.1 Market Trend
2.1.4.4.2 Market Size and Forecast
2.1.4.4.3 Medical Bill and Fee
2.1.4.4.3.1 North America
2.1.4.4.3.2 Europe
2.1.4.4.3.3 Asia-Pacific
2.1.4.4.3.4 Rest-of-the-World
2.1.4.5 Parkinson’s Disease
2.1.4.5.1 Market Trend
2.1.4.5.2 Market Size and Forecast
2.1.4.5.3 Medical Bill and Fee
2.1.4.5.3.1 North America
2.1.4.5.3.2 Europe
2.1.4.5.3.3 Asia-Pacific
2.1.4.5.3.4 Rest-of-the-World
2.1.4.6 Motor Neuron Disease
2.1.4.6.1 Market Trend
2.1.4.6.2 Market Size and Forecast
2.1.4.6.3 Medical Bill and Fee
2.1.4.6.3.1 North America
2.1.4.6.3.2 Europe
2.1.4.6.3.3 Asia-Pacific
2.1.4.6.3.4 Rest-of-the-World
2.1.4.7 Other Neurodegenerative Diseases
2.1.4.7.1 Market Trend
2.1.4.7.2 Market Size and Forecast
2.1.4.7.3 Medical Bill and Fee
2.1.4.7.3.1 North America
2.1.4.7.3.2 Europe
2.1.4.7.3.3 Asia-Pacific
2.1.4.7.3.4 Rest-of-the-World
2.2 Global Brain Disease Modalities and Software Market (by Patient Type)
2.2.1 Opportunity Assessment
2.2.2 Adults
2.2.2.1 Market Trends
2.2.2.2 Market Size and Forecast
2.2.3 Pediatrics and Infants
2.2.3.1 Market Trends
2.2.3.2 Market Size and Forecast
2.3 Global Brain Disease Modalities and Software Market (by End User)
2.3.1 Opportunity Assessment
2.3.2 Hospitals and Clinics
2.3.3 Diagnostic Imaging Centers
2.3.4 Ambulatory Surgery Centers
3 Products
3.1 Brain Disease Modalities and Software Market (by Product)
3.1.1 Opportunity Assessment
3.1.2 Growth Share Matrix
3.1.3 Brain Modalities
3.1.3.1 Market Size and Forecast
3.1.3.2 by Type
3.1.3.2.1 PET Devices
3.1.3.2.2 PET-CT
3.1.3.2.3 PET-MRI
3.1.3.2.4 CT Devices
3.1.3.2.5 MRI Devices
3.1.4 Brain Analysis Software
3.1.4.1 Market Trends
3.1.4.1.1 North America
3.1.4.1.2 Europe
3.1.4.1.3 Asia-Pacific
3.1.4.1.4 Rest-of-the-World
3.1.4.2 Pricing Analysis
3.1.4.3 Vendor Trends
3.1.4.3.1 Market Share Analysis
3.1.4.3.2 Skills Analysis
3.1.4.3.3 Purpose/Application Analysis
3.1.4.3.4 Target Disease Analysis
3.1.4.3.5 Modality Analysis
3.1.4.3.6 Analytical Report Status
3.1.4.3.7 Regulatory Status Analysis
4 Region
4.1 North America Brain Disease Modalities and Software Market
4.1.1 Market
4.1.1.1 Regulatory Framework
4.1.1.2 Opportunity Assessment
4.1.1.3 Market Dynamics
4.1.1.3.1 Impact Analysis
4.1.1.4 Sizing and Forecast Analysis
4.1.2 Application
4.1.2.1 North America Brain Disease Modalities and Software Market (by Indication)
4.1.2.2 North America Brain Disease Modalities and Software Market (by Patient Type)
4.1.2.3 North America Brain Disease Modalities and Software Market (by End User)
4.1.3 Product
4.1.3.1 North America Brain Disease Modalities and Software Market (by Product)
4.1.4 North America Brain Disease Modalities and Software Market (by Country)
4.1.4.1 U.S.
4.1.4.2 Canada
4.2 Europe Brain Disease Modalities and Software Market
4.2.1 Market
4.2.1.1 Regulatory Framework
4.2.1.2 Opportunity Assessment
4.2.1.3 Market Dynamics
4.2.1.3.1 Impact Analysis
4.2.1.4 Sizing and Forecast Analysis
4.2.2 Application
4.2.2.1 Europe Brain Disease Modalities and Software Market (by Indication)
4.2.2.2 Europe Brain Disease Modalities and Software Market (by Patient Type)
4.2.2.3 Europe Brain Disease Modalities and Software Market (by End User)
4.2.3 Product
4.2.3.1 Europe Brain Disease Modalities and Software Market (by Product)
4.2.4 Europe Brain Disease Modalities and Software Market (by Country)
4.2.4.1 Germany
4.2.4.2 U.K.
4.2.4.3 France
4.2.4.4 Italy
4.2.4.5 Spain
4.2.4.6 Rest-of-Europe
4.3 Asia-Pacific Brain Disease Modalities and Software Market
4.3.1 Market
4.3.1.1 Regulatory Framework
4.3.1.2 Opportunity Assessment
4.3.1.3 Market Dynamics
4.3.1.3.1 Impact Analysis
4.3.1.4 Sizing and Forecast Analysis
4.3.2 Application
4.3.2.1 Asia-Pacific Brain Disease Modalities and Software Market (by Indication)
4.3.2.2 Asia-Pacific Brain Disease Modalities and Software Market (by Patient Type)
4.3.2.3 Asia-Pacific Brain Disease Modalities and Software Market (by End User)
4.3.3 Product
4.3.3.1 Asia-Pacific Brain Disease Modalities and Software Market (by Product)
4.3.4 Asia-Pacific Brain Disease Modalities and Software Market (by Country)
4.3.4.1 Japan
4.3.4.2 China
4.3.4.3 India
4.3.4.4 South Korea
4.3.4.5 Australia and New Zealand
4.3.4.6 Rest-of-Asia-Pacific
4.4 Rest-of-the-World Brain Disease Modalities and Software Market
4.4.1 Market
4.4.1.1 Regulatory Framework
4.4.1.2 Opportunity Assessment
4.4.1.3 Market Dynamics
4.4.1.3.1 Impact Analysis
4.4.1.4 Sizing and Forecast Analysis
4.4.2 Application
4.4.2.1 Rest-of-the-World Brain Disease Modalities and Software Market (by Indication)
4.4.2.2 Rest-of-the-World Brain Disease Modalities and Software Market (by Patient Type)
4.4.2.3 Rest-of-the-World Brain Disease Modalities and Software Market (by End User)
4.4.3 Product
4.4.3.1 Rest-of-the-World Brain Disease Modalities and Software Market (by Product)
4.4.4 Rest-of-the-World Brain Disease Modalities and Software Market (by Region)
4.4.4.1 Latin America
4.4.4.2 Middle East and Africa
5 Markets – Competitive Benchmarking & Company Profiles
5.1 Competitive Benchmarking and Company Profiles
5.1.1 Competitive Landscape
5.1.1.1 Key Strategies and Developments
5.1.1.1.1 Partnerships, Alliances, and Business Expansions
5.1.1.1.2 Funding Activities
5.1.1.1.3 New Offerings
5.1.1.1.4 Mergers and Acquisitions
5.1.1.1.5 Regulatory and Legal Activities
5.2 Market Share Analysis
5.3 Company Profiles
5.3.1 Brain Disease Modalities and Software Companies
5.3.1.1 United Imaging Healthcare Co., Ltd.
5.3.1.1.1 Company Overview
5.3.1.1.2 Role of United Imaging Healthcare Co., Ltd. in the Global Brain Disease Modalities and Software Market
5.3.1.1.3 Product Portfolio and Offerings
5.3.1.1.4 Recent Developments
5.3.1.1.5 SWOT Analysis
5.3.1.2 Koninklijke Philips N.V.
5.3.1.2.1 Company Overview
5.3.1.2.2 Role of Koninklijke Philips N.V. in the Global Brain Disease Modalities and Software Market
5.3.1.2.3 Product Portfolio and Offerings
5.3.1.2.4 Financials
5.3.1.2.5 SWOT Analysis
5.3.1.3 General Electric Company
5.3.1.3.1 Company Overview
5.3.1.3.2 Role of General Electric Company in the Global Brain Disease Modalities and Software Market
5.3.1.3.3 Product Portfolio and Offerings
5.3.1.3.4 Financials
5.3.1.3.5 SWOT Analysis
5.3.1.4 Canon, Inc.
5.3.1.4.1 Company Overview
5.3.1.4.2 Role of Canon, Inc. in the Global Brain Disease Modalities and Software Market
5.3.1.4.3 Product Portfolio and Offerings
5.3.1.4.4 Recent Developments
5.3.1.4.5 Financials
5.3.1.4.6 SWOT Analysis
5.3.1.5 Siemens Healthineers AG
5.3.1.5.1 Company Overview
5.3.1.5.2 Role of Siemens Healthineers AG in the Global Brain Disease Modalities and Software Market
5.3.1.5.3 Product Portfolio and Offerings
5.3.1.5.4 Financials
5.3.1.5.5 Recent Developments
5.3.1.5.6 SWOT Analysis
5.3.1.6 Vuno Co., Ltd.
5.3.1.6.1 Company Overview
5.3.1.6.2 Role of Vuno Co., Ltd. in the Global Brain Disease Modalities and Software Market
5.3.1.6.3 Product Portfolio and Offerings
5.3.1.6.4 Recent Developments
5.3.1.6.5 SWOT Analysis
5.3.1.7 Fujifilm Holdings Corporation
5.3.1.7.1 Company Overview
5.3.1.7.2 Role of Fujifilm Holdings Corporation in the Global Brain Disease Modalities and Software Market
5.3.1.7.3 Product Portfolio
5.3.1.7.4 Financials
5.3.1.7.5 Recent Developments
5.3.1.7.6 SWOT Analysis
5.3.1.8 Aspect Imaging
5.3.1.8.1 Company Overview
5.3.1.8.2 Role of Aspect Imaging in the Global Brain Disease Modalities and Software Market
5.3.1.8.3 Product Portfolio and Offerings
5.3.1.8.4 SWOT Analysis
5.3.2 Brain Imaging Software Companies
5.3.2.1 IXICO
5.3.2.1.1 Company Overview
5.3.2.1.2 Role of IXICO in the Global Brain Disease Modalities and Software Market
5.3.2.1.3 Product Portfolio and Offerings
5.3.2.1.4 Financials
5.3.2.1.5 Recent Developments
5.3.2.1.6 SWOT Analysis
5.3.2.2 QMENTA
5.3.2.2.1 Company Overview
5.3.2.2.2 Role of QMENTA in the Global Brain Disease Modalities and Software Market
5.3.2.2.3 Product Portfolio and Offerings
5.3.2.2.4 SWOT Analysis
5.3.2.3 Cortechs.ai
5.3.2.3.1 Company Overview
5.3.2.3.2 Role of Cortechs.ai in the Global Brain Disease Modalities and Software Market
5.3.2.3.3 Product Portfolio and Offerings
5.3.2.3.4 Recent Developments
5.3.2.3.5 SWOT Analysis
5.3.2.4 Quantib
5.3.2.4.1 Company Overview
5.3.2.4.2 Role of Quantib in the Global Brain Disease Modalities and Software Market
5.3.2.4.3 Product Portfolio and Offerings
5.3.2.4.4 Recent Developments
5.3.2.4.5 SWOT Analysis
5.3.2.5 Brainomix
5.3.2.5.1 Company Overview
5.3.2.5.2 Role of Brainomix in the Global Brain Disease Modalities and Software Market
5.3.2.5.3 Product Portfolio and Offerings
5.3.2.5.4 Recent Developments
5.3.2.5.5 SWOT Analysis
5.3.2.6 Qure.AI
5.3.2.6.1 Company Overview
5.3.2.6.2 Role of Qure.AI in the Global Brain Disease Modalities and Software Market
5.3.2.6.3 Product Portfolio and Offerings
5.3.2.6.4 Recent Developments
5.3.2.6.5 SWOT Analysis
5.3.2.7 Imaging Biometrics, LLC
5.3.2.7.1 Company Overview
5.3.2.7.2 Role of Imaging Biometrics, LLC in the Global Brain Disease Modalities and Software Market
5.3.2.7.3 Product Portfolio and Offerings
5.3.2.7.4 Recent Developments
5.3.2.7.5 SWOT Analysis
5.3.2.8 A.I. Analysis, Inc.
5.3.2.8.1 Company Overview
5.3.2.8.2 Role of A.I. Analysis, Inc. in the Global Brain Disease Modalities and Software Market
5.3.2.8.3 Product Portfolio and Offerings
5.3.2.8.4 SWOT Analysis
6 Research Methodology
6.1 Data Collection and Analysis
6.2 Data Sources
6.2.1 Primary Data Sources
6.2.2 Secondary Data Sources
6.3 Data Triangulation
6.4 Market Estimation
6.5 Forecast Period Selection Criteria
6.6 Assumptions and Limitations
List of Figures
Figure 1: Global Brain Disease Modalities and Software Market, Impact Analysis
Figure 2: Market Size Forecast (by Region), 2021 and 2031
Figure 3: Global Brain Disease Modalities and Software Market, Overall Coverage
Figure 4: Global Brain Disease Modalities and Software Market, Potential Forecast Scenarios
Figure 5: Global Brain Disease Modalities and Software Market Size and Growth Potential (Realistic Scenario), $Million, 2020-2031
Figure 6: Global Brain Disease Modalities and Software Market Size and Growth Potential (Optimistic Scenario), $Million, 2020-2031
Figure 7: Global Brain Disease Modalities and Software Market Size and Growth Potential (Pessimistic Scenario/Conservative Growth), $Million, 2020-2031
Figure 8: Global Brain Disease Modalities and Software Market, Key Technology Trends
Figure 9: Global Brain Disease Modalities and Software Market Key Trends, Short-Term Potential
Figure 10: Global Brain Disease Modalities and Software Market Key Trends, Long-Term Potential
Figure 11: Global Brain Disease Modalities and Software Market Patent Analysis (by Country/Cluster), 2018-2021
Figure 12: Global Brain Disease Modalities and Software Market Patent Analysis (by Year), 2018-2021
Figure 13: Global Brain Disease Modalities and Software Market, Pre-COVID-19 Phase, $Million, 2018-2031
Figure 14: Global Brain Disease Modalities and Software Market, Impact Analysis
Figure 15: Global Brain Disease Modalities and Software Market, Prevalence of Brain Diseases, 2010, 2015, and 2019
Figure 16: Global Brain Disease Modalities and Software Market, Prevalence of Neurodegenerative Diseases, 2010, 2015, and 2019
Figure 17: Global Brain Disease Modalities and Software Market, Role of AI in Medical Imaging
Figure 18: Global Brain Disease Modalities and Software Market (by Indication)
Figure 19: Global Brain Disease Modalities and Software Market Incremental Opportunity (by Indication), $Million, 2021-2031
Figure 20: Global Brain Disease Modalities and Software Market, Growth Share Matrix (by Indication), 2021-2031
Figure 21: Global Brain Disease Modalities and Software Market (Brain and Central Nervous System Cancer), $Million, 2020-2031
Figure 22: Global Brain Disease Modalities and Software Market (Idiopathic Epilepsy), $Million, 2020-2031
Figure 23: Global Brain Disease Modalities and Software Market (Ischemic Stroke), $Million, 2020-2031
Figure 24: Global Brain Disease Modalities and Software Market (Other Brain Diseases), $Million, 2020-2031
Figure 25: Global Brain Disease Modalities and Software Market (Alzheimer’s Disease), $Million, 2020-2031
Figure 26: Global Brain Disease Modalities and Software Market (Multiple Sclerosis), $Million, 2020-2031
Figure 27: Global Brain Disease Modalities and Software Market (Parkinson’s Disease), $Million, 2020-2031
Figure 28: Global Brain Disease Modalities and Software Market (Motor Neuron Disease), $Million, 2020-2031
Figure 29: Global Brain Disease Modalities and Software Market (Other Neurodegenerative Diseases), $Million, 2020-2031
Figure 30: Global Brain Disease Modalities and Software Market (by Patient Type)
Figure 31: Global Brain Disease Modalities and Software Market Incremental Opportunity (by Patient Type), $Million, 2021-2031
Figure 32: Global Brain Disease Modalities and Software Market (Adults), $Million, 2020-2031
Figure 33: Global Brain Disease Modalities and Software Market (Pediatrics and Infants), $Million, 2020-2031
Figure 34: Global Brain Disease Modalities and Software Market (by End User)
Figure 35: Global Brain Disease Modalities and Software Market, Incremental Opportunity (by End User), $Million, 2021-2031
Figure 36: Global Brain Disease Modalities and Software Market (Hospitals and Clinics), $Million, 2020-2031
Figure 37: Global Brain Disease Modalities and Software Market (Diagnostic Imaging Centers), $Million, 2020-2031
Figure 38: Global Brain Disease Modalities and Software Market (Ambulatory Surgery Centers), $Million, 2020-2031
Figure 39: Global Brain Disease Modalities and Software Market (by Product)
Figure 40: Global Brain Disease Modalities and Software Market, Incremental Opportunity (by Product), $Million, 2021-2031
Figure 41: Global Brain Disease Modalities and Software Market, Growth Share Matrix (by Product), 2021-2031
Figure 42: Global Brain Disease Modalities and Software Market (by Brain Modalities), $Million, 2020-2031
Figure 43: North America Brain Disease Modalities and Software Market, PET Devices, $Million, 2020-2031
Figure 44: North America Brain Disease Modalities and Software Market, PET-CT, $Million, 2020-2031
Figure 45: North America Brain Disease Modalities and Software Market, PET-MRI, $Million, 2020-2031
Figure 46: North America Brain Disease Modalities and Software Market, CT Devices, $Million, 2020-2031
Figure 47: North America Brain Disease Modalities and Software Market, MRI Devices, $Million, 2020-2031
Figure 48: North America Brain Disease Modalities and Software Market, Brain Analysis Software, $Million, 2020-2031
Figure 49: Global Brain Analysis Software Market, Company Revenue Share Analysis, $Million, 2021
Figure 50: Global Brain Disease Modalities and Software Market (by Region), $Million, 2020-2031
Figure 51: North America Brain Disease Modalities and Software Market, Incremental Revenue Opportunity (by Country), $Million, 2021-2031
Figure 52: North America Brain Disease Modalities and Software Market, $Million, 2020-2031
Figure 53: North America Brain Disease Modalities and Software Market (by Indication), $Million, 2020-2031
Figure 54: North America Brain Disease Modalities and Software Market (by Brain Diseases), $Million, 2020-2031
Figure 55: North America Brain Disease Modalities and Software Market (by Neurodegenerative Diseases), $Million, 2020-2031
Figure 56: North America Brain Disease Modalities and Software Market (by Patient Type), $Million, 2020-2031
Figure 57: North America Brain Disease Modalities and Software Market (by End User), $Million, 2020-2031
Figure 58: North America Brain Disease Modalities and Software Market (by Product), $Million, 2020-2031
Figure 59: North America Brain Disease Modalities and Software Market (by Country), $Million, 2021 and 2031
Figure 60: U.S. Brain Disease Modalities and Software Market, $Million, 2020-2031
Figure 61: Canada Brain Disease Modalities and Software Market, $Million, 2020-2031
Figure 62: Europe Brain Disease Modalities and Software Market Incremental Revenue Opportunity (by Country), $Million, 2021-2031
Figure 63: Europe Brain Disease Modalities and Software Market, $Million, 2020-2031
Figure 64: Europe Brain Disease Modalities and Software Market (by Indication), $Million, 2020-2031
Figure 65: Europe Brain Disease Modalities and Software Market (by Brain Diseases), $Million, 2020-2031
Figure 66: Europe Brain Disease Modalities and Software Market (by Neurodegenerative Diseases), $Million, 2020-2031
Figure 67: Europe Brain Disease Modalities and Software Market (by Patient Type), $Million, 2020-2031
Figure 68: Europe Brain Disease Modalities and Software Market (by End User), $Million, 2020-2031
Figure 69: Europe Brain Disease Modalities and Software Market (by Product), $Million, 2020-2031
Figure 70: Europe Brain Disease Modalities and Software Market (by Country), $Million, 2021 and 2031
Figure 71: Germany Brain Disease Modalities and Software Market, $Million, 2020-2031
Figure 72: U.K. Brain Disease Modalities and Software Market, $Million, 2020-2031
Figure 73: France Brain Disease Modalities and Software Market, $Million, 2020-2031
Figure 74: Italy Brain Disease Modalities and Software Market, $Million, 2020-2031
Figure 75: Spain Brain Disease Modalities and Software Market, $Million, 2020-2031
Figure 76: Rest-of-Europe Brain Disease Modalities and Software Market, $Million, 2020-2031
Figure 77: Asia-Pacific Brain Disease Modalities and Software Market, Incremental Revenue Opportunity (by Country), $Million, 2021-2031
Figure 78: Asia-Pacific Brain Disease Modalities and Software Market, $Million, 2020-2031
Figure 79: Asia-Pacific Brain Disease Modalities and Software Market (by Indication), $Million, 2020-2031
Figure 80: Asia-Pacific Brain Disease Modalities and Software Market (by Brain Diseases), $Million, 2020-2031
Figure 81: Asia-Pacific Brain Disease Modalities and Software Market (by Neurodegenerative Diseases), $Million, 2020-2031
Figure 82: Asia-Pacific Brain Disease Modalities and Software Market (by Patient Type), $Million, 2020-2031
Figure 83: Asia-Pacific Brain Disease Modalities and Software Market (by End User), $Million, 2020-2031
Figure 84: Asia-Pacific Brain Disease Modalities and Software Market (by Product), $Million, 2020-2031
Figure 85: Asia-Pacific Brain Disease Modalities and Software Market (by Country), $Million, 2021 and 2031
Figure 86: Japan Brain Disease Modalities and Software Market, $Million, 2020-2031
Figure 87: China Brain Disease Modalities and Software Market, $Million, 2020-2031
Figure 88: India Brain Disease Modalities and Software Market, $Million, 2020-2031
Figure 89: South Korea Brain Disease Modalities and Software Market, $Million, 2020-2031
Figure 90: Australia and New Zealand Brain Disease Modalities and Software Market, $Million, 2020-2031
Figure 91: Rest-of-Asia-Pacific Brain Disease Modalities and Software Market, $Million, 2020-2031
Figure 92: Rest-of-the-World Brain Disease Modalities and Software Market Incremental Revenue Opportunity (by Country), $Million, 2021-2031
Figure 93: Rest-of-the-World Brain Disease Modalities and Software Market, $Million, 2020-2031
Figure 94: Rest-of-the-World Brain Disease Modalities and Software Market (by Indication), $Million, 2020-2031
Figure 95: Rest-of-the-World Brain Disease Modalities and Software Market (by Brain Diseases), $Million, 2020-2031
Figure 96: Rest-of-the-World Brain Disease Modalities and Software Market (by Neurodegenerative Diseases), $Million, 2020-2031
Figure 97: Rest-of-the-World Brain Disease Modalities and Software Market (by Patient Type), $Million, 2020-2031
Figure 98: Rest-of-the-World Brain Disease Modalities and Software Market (by End User), $Million, 2020-2031
Figure 99: Rest-of-the-World Brain Disease Modalities and Software Market (by Product), $Million, 2020-2031
Figure 100: Rest-of-the-World Brain Disease Modalities and Software Market (by Region), $Million, 2021 and 2031
Figure 101: Latin America Brain Disease Modalities and Software Market, $Million, 2020-2031
Figure 102: Middle East and Africa Brain Disease Modalities and Software Market, $Million, 2020-2031
Figure 103: Partnerships, Alliances, and Business Expansions (by Company), January 2018-December 2021
Figure 104: Funding Activities (by Company), January 2018-December 2021
Figure 105: New Offerings (by Company), January 2018-December 2021
Figure 106: Mergers and Acquisitions (by Company), January 2018-December 2021
Figure 107: Mergers and Acquisitions (by Company), January 2018-December 2021
Figure 108: Global Brain Disease Modalities and Software Market, Company Revenue Share Analysis, $Million, 2021
Figure 109: United Imaging Healthcare Co., Ltd.: Overall Product Portfolio
Figure 110: Koninklijke Philips N.V.: Overall Product Portfolio
Figure 111: Koninklijke Philips N.V.: Overall Financials, $Million, 2018-2020
Figure 112: Koninklijke Philips N.V.: Net Revenue (by Segment), $Million, 2018-2020
Figure 113: Koninklijke Philips N.V.: Net Revenue (by Region), $Million, 2018-2020
Figure 114: Koninklijke Philips N.V.: R&D Expenditure, $Million, 2018-2020
Figure 115: General Electric Company: Overall Product Portfolio
Figure 116: General Electric Company: Overall Financials, $Million, 2018-2020
Figure 117: General Electric Company: Net Revenue (by Segment), $Million, 2018-2020
Figure 118: General Electric Company: Net Revenue (by Region), $Million, 2018-2020
Figure 119: General Electric Company: R&D Expenditure, $Million, 2018-2020
Figure 120: Canon, Inc.: Overall Product Portfolio
Figure 121: Canon, Inc.: Overall Financials, $Million, 2018-2020
Figure 122: Canon, Inc.: Net Revenue (by Segment), $Million, 2018-2020
Figure 123: Canon, Inc.: Revenue (by Region), $Million, 2018-2020
Figure 124: Canon, Inc.: R&D Expenditure, $Million, 2018-2020
Figure 125: Siemens Healthineers AG: Overall Product Portfolio
Figure 126: Siemens Healthineers AG: Overall Financials, $Million, 2019-2021
Figure 127: Siemens Healthineers AG: Net Revenue (by Segment), $Million, 2019-2021
Figure 128: Siemens Healthineers AG: Net Revenue (by Region), $Million, 2019-2021
Figure 129: Siemens Healthineers AG: R&D Expenditure, $Million, 2019-2021
Figure 130: Vuno Co., Ltd.: Product Portfolio
Figure 131: Fujifilm Holdings Corporation: Product Portfolio
Figure 132: Fujifilm Holdings Corporation: Overall Financials, $Million, 2018-2020
Figure 133: Fujifilm Holdings Corporation: Net Revenue (by Segment), $Million, 2018-2020
Figure 134: Fujifilm Holdings Corporation: Net Revenue (by Region), $Million, 2018-2020
Figure 135: Fujifilm Holdings Corporation: R&D Expenditure, $Million, 2018-2020
Figure 136: Aspect Imaging: Product Offerings
Figure 137: IXICO: Product Portfolio
Figure 138: IXICO: Overall Financials, $Million, 2019-2021
Figure 139: IXICO (by Region), $Million, 2020-2021
Figure 140: IXICO: R&D Expenditure, $Million, 2019-2021
Figure 141: QMENTA: Product Portfolio
Figure 142: Cortechs.ai: Product Portfolio
Figure 143: Quantib: Product Portfolio
Figure 144: Brainomix: Product Portfolio
Figure 145: Qure.AI: Product Portfolio
Figure 146: Imaging Biometrics, LLC: Product Portfolio
Figure 147: A.I. Analysis, Inc.: Product Portfolio
Figure 148: Global Brain Disease Modalities and Software Market: Research Methodology
Figure 149: Primary Research
Figure 150: Secondary Research
Figure 151: Data Triangulation
Figure 152: Global Brain Disease Modalities and Software Market Research Process
Figure 153: Assumptions and Limitations
List of Tables
Table 1: Key Challenges and Possible Solutions for Players in the Global Brain Disease Modalities and Software Market
Table 2: Global Brain Disease Modalities and Software Market, Quarterly Key Developments Analysis, January 2018-December 2021
Table 3: Global Brain Disease Modalities and Software Market, Product Offerings, by Modality Types and Software
Table 4: Global Brain Disease Modalities and Software Market, Strength of Product Offerings, by Modality Types and Software
Table 5: Global Brain Disease Modalities and Software Market, Patient Volume of Brain Diseases
Table 6: Global Brain Disease Modalities and Software Market, Key Modalities Analysis for Brain and Central Nervous System Cancer
Table 7: Global Brain Disease Modalities and Software Market, Key Modalities Analysis for Idiopathic Epilepsy
Table 8: Global Brain Disease Modalities and Software Market, Key Modalities Analysis for Ischemic Stroke
Table 9: Global Brain Disease Modalities and Software Market, Key Modalities Analysis for Other Brain Diseases
Table 10: Global Brain Disease Modalities and Software Market, Patient Volume of Neurodegenerative Diseases
Table 11: Global Brain Disease Modalities and Software Market, Imaging Fee, North America
Table 12: Global Brain Disease Modalities and Software Market, Imaging Fee, Europe
Table 13: Global Brain Disease Modalities and Software Market, Imaging Fee, Asia-Pacific
Table 14: Global Brain Disease Modalities and Software Market, Imaging Fee, Rest-of-the-World
Table 15: Global Brain Disease Modalities and Software Market, Imaging Fee, North America
Table 16: Global Brain Disease Modalities and Software Market, Imaging Fee, Europe
Table 17: Global Brain Disease Modalities and Software Market, Imaging Fee, Asia-Pacific
Table 18: Global Brain Disease Modalities and Software Market, Imaging Fee, Rest-of-the-World
Table 19: Global Brain Disease Modalities and Software Market, Imaging Fee, North America
Table 20: Global Brain Disease Modalities and Software Market, Imaging Fee, Europe
Table 21: Global Brain Disease Modalities and Software Market, Imaging Fee, Asia-Pacific
Table 22: Global Brain Disease Modalities and Software Market, Imaging Fee, Rest-of-the-World
Table 23: Global Brain Disease Modalities and Software Market, Imaging Fee, North America
Table 24: Global Brain Disease Modalities and Software Market, Imaging Fee, Europe
Table 25: Global Brain Disease Modalities and Software Market, Imaging Fee, Asia-Pacific
Table 26: Global Brain Disease Modalities and Software Market, Imaging Fee, Rest-of-the-World
Table 27: Global Brain Disease Modalities and Software Market, Imaging Fee, North America
Table 28: Global Brain Disease Modalities and Software Market, Imaging Fee, Europe
Table 29: Global Brain Disease Modalities and Software Market, Imaging Fee, Asia-Pacific
Table 30: Global Brain Disease Modalities and Software Market, Imaging Fee, Rest-of-the-World
Table 31: Global Brain Disease Modalities and Software Market, Pricing Analysis, by Company Type
Table 32: Global Brain Disease Modalities and Software Market, Pricing Analysis, by Software Type
Table 33: Global Brain Disease Modalities and Software Market, Skills Analysis
Table 34: Global Brain Disease Modalities and Software Market, Application Analysis
Table 35: Global Brain Disease Modalities and Software Market, Target Disease Analysis
Table 36: Global Brain Disease Modalities and Software Market, Modality Analysis
Table 37: Global Brain Disease Modalities and Software Market, Analytical Report Analysis
Table 38: Global Brain Disease Modalities and Software Analysis, Regulatory Status (FDA and CE)
Table 39: North America Brain Disease Modalities and Software Market Regulations
Table 40: North America Brain Disease Modalities and Software Market, Impact Analysis
Table 41: Europe Brain Disease Modalities and Software Market Regulations
Table 42: Europe Brain Disease Modalities and Software Market, Impact Analysis
Table 43: Asia-Pacific Brain Disease Modalities and Software Market Regulations
Table 44: Asia-Pacific Brain Disease Modalities and Software Market, Impact Analysis
Table 45: Rest-of-the-World Brain Disease Modalities and Software Market, Impact Analysis
Table 46: Secondary Data Sources

Companies Mentioned

United Imaging Healthcare Co., Ltd.
Koninklijke Philips N.V.
General Electric Company
Canon, Inc.
Siemens Healthineers AG
Vuno Co., Ltd.
Fujifilm Holdings Corporation
Aspect Imaging
IXICO
QMENTA
Cortechs.ai
Quantib
Brainomix
Qure.AI
Imaging Biometrics, LLC
A.I. Analysis, Inc.

Reviews

There are no reviews yet.

Be the first to review “Brain Disease Modalities and Software Market – A Global and Regional Analysis: Focus on Product, Indication, Patient Type, End User, and Regional Analysis – Analysis and Forecast, 2022-2031”

[class^="wpforms-"]
[class^="wpforms-"]